Vestibular Migraine Treatment and Diagnosis

Introduction to Vestibular Migraine

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that vestibular migraine has a lifetime prevalence of 3.2%, accounting for up to 14% of vertigo cases 1, 2
• The diagnostic criteria for vestibular migraine include ≥5 episodes of vestibular symptoms lasting 5 minutes to 72 hours 3
• Other causes of vertigo, such as central causes (stroke, multiple sclerosis), should be ruled out by appropriate investigations 1, 2

Treatment Approaches

• The first-line treatment for vestibular migraine includes lifestyle modifications, followed by preventive medications such as beta blockers (e.g. atenolol), topiramate, or candesartan when symptoms occur ≥2 days per month despite optimized acute treatment 4
• Non-pharmacological approaches, including stress reduction techniques, regular sleep schedule, and biobehavioral therapy, can be effective in managing vestibular migraine symptoms 4
• Antiemetic medications, such as diphenhydramine and meclizine, can help ameliorate symptoms during acute attacks 3
• Triptans can be used to treat concurrent headache in patients with vestibular migraine 4

Pharmacological Treatment

• Beta blockers, such as atenolol and propranolol, are first-line preventive medications for vestibular migraine 4
• Topiramate and candesartan are also first-line preventive medications for vestibular migraine 4
• CGRP monoclonal antibodies, such as erenumab, fremanezumab, galcanezumab, and eptinezumab, can be used as third-line preventive medications for vestibular migraine 4

Diagnostic Considerations

• Vestibular migraine should be distinguished from other causes of vertigo, such as benign paroxysmal positional vertigo (BPPV), Ménière's disease, and vestibular neuritis 3
• Central causes of vertigo, such as stroke and multiple sclerosis, should also be considered in the differential diagnosis 1, 2

Common Pitfalls to Avoid

• Overuse of vestibular suppressant medications, which are not recommended for long-term management, should be avoided 3
• Inadequate follow-up to assess treatment response should be avoided 3

Management of Vestibular Migraine

Acute Management

• The American Academy of Otolaryngology-Head and Neck Surgery recommends vestibular suppressants for acute attacks, but not for long-term use, and notes that centrally acting anticholinergic drugs like scopolamine can suppress acute vertigo attacks, although with significant side effects, and benzodiazepines may help with acute symptoms but carry a risk of drug dependence 5

Preventive Treatment

• The American Academy of Neurology suggests that onabotulinumtoxinA may be considered for chronic migraine with vestibular symptoms 6

Lifestyle Modifications

• The American Academy of Otolaryngology-Head and Neck Surgery recommends dietary and lifestyle modifications as first-line interventions, including limiting salt/sodium intake, avoiding excessive caffeine, alcohol, and nicotine, eating well-balanced meals, maintaining adequate hydration, managing stress, regular exercise, establishing regular sleep patterns, and identifying and managing allergies 5

Non-Pharmacological Approaches

• The American Academy of Otolaryngology-Head and Neck Surgery notes that patient education is essential to improve understanding and adherence to treatment plans 5

Common Pitfalls to Avoid

• The Nature Reviews Neurology warns against failure to recognize and manage comorbidities such as anxiety, depression, and sleep disturbances, and overuse of acute medications, which can lead to medication overuse headache 6

Management of Vestibular Migraine with Pharmacological Interventions

Treatment Duration and Assessment

• Assess efficacy of oral preventive medications after 2-3 months at therapeutic dose, and consider pausing treatment after 6-12 months of successful control to determine if preventive therapy can be stopped, as recommended by the American Academy of Neurology 7
• For CGRP monoclonal antibodies, assess efficacy after 3-6 months, and for onabotulinumtoxinA, assess efficacy after 6-9 months, according to guidelines from the American Headache Society 7

Patient Education

• Emphasize that treatment adherence improves with simplified dosing schedules, and set realistic expectations that efficacy is rarely observed immediately and may take several weeks to months, as suggested by the American Academy of Neurology 7
• Explain that failure of one preventive treatment does not predict failure of other drug classes, and educate patients on the importance of adherence to treatment, as recommended by the American Migraine Foundation 7

Critical Pitfalls to Avoid

• Avoid overuse of acute medications, as this risks medication overuse headache, and do not abandon treatment prematurely, as efficacy takes weeks to months to establish, according to the International Headache Society 7
• Avoid oral ergot alkaloids, opioids, and barbiturates due to questionable efficacy with considerable adverse effects and dependency risk, as warned by the American Academy of Neurology 7

Prevention of Vestibular Migraine

First-Line Preventive Strategies

• The American Academy of Neurology recommends beta blockers, such as propranolol, metoprolol, atenolol, or bisoprolol, as first-line agents for patients with vestibular migraine, particularly those with comorbid hypertension 8
• Topiramate is a first-line option, especially beneficial in obese patients with vestibular migraine 8
• Candesartan is a first-line angiotensin receptor blocker option for patients with vestibular migraine 8

Second-Line Preventive Medications

• Flunarizine, a calcium channel blocker, is effective for vestibular migraine prevention in patients who fail first-line agents 8
• Amitriptyline or nortriptyline, tricyclic antidepressants, are particularly useful for patients with vestibular migraine and coexisting anxiety or depression 8
• Valproic acid, an anticonvulsant, is an option for men with vestibular migraine, but should be avoided in women of childbearing potential 8

Third-Line and Refractory Cases

• CGRP monoclonal antibodies, such as erenumab, fremanezumab, galcanezumab, and eptinezumab, should be considered as third-line medications for patients with vestibular migraine who have failed first- and second-line agents 8

Non-Pharmacological Preventive Approaches

• Biobehavioral therapy, including relaxation techniques, stress management, and biofeedback, can be as effective as pharmacological approaches and should be combined with medication for patients with vestibular migraine 8
• Neuromodulatory devices can be considered as adjuncts or stand-alone treatment for patients with vestibular migraine when medication is contraindicated 8
• Acupuncture has some supporting evidence for vestibular migraine prevention, though not superior to sham acupuncture 8

Vestibular Migraine Management

Pharmacological Interventions

• The American Academy of Neurology recommends topiramate 50-100 mg oral daily as a first-line option for vestibular migraine prevention, especially beneficial in obese patients 9
• The American Academy of Neurology suggests amitriptyline 10-100 mg oral at night or nortriptyline as second-line options for patients with coexisting anxiety or depression 9
• The American Academy of Neurology recommends flunarizine 5-10 mg oral once daily as a second-line option for prevention in patients who fail first-line agents, though it should be avoided in patients with Parkinsonism or depression 9
• The American Academy of Neurology suggests valproic acid 600-1,500 mg oral once daily as a second-line option for men, but it is absolutely contraindicated in women of childbearing potential due to teratogenicity 9
• The American Academy of Neurology recommends CGRP monoclonal antibodies (erenumab 70 or 140 mg subcutaneous once monthly, fremanezumab 225 mg subcutaneous once monthly or 675 mg quarterly, eptinezumab 100 or 300 mg intravenous quarterly) as third-line medications for refractory cases 9
• The American Academy of Neurology suggests onabotulinumtoxinA 155-195 units to 31-39 sites every 12 weeks as a third-line option for chronic migraine with vestibular symptoms 9
• The American Academy of Family Physicians advises against the use of oral ergot alkaloids, opioids, and barbiturates due to questionable efficacy with considerable adverse effects and dependency risk 10

Treatment Assessment and Duration

• The American Academy of Neurology recommends assessing efficacy of oral preventive medications after 2-3 months at therapeutic dose, and considering pausing treatment after 6-12 months of successful control to determine if preventive therapy can be stopped 9

Vestibular Migraine Management

Medication Considerations

• The American Academy of Family Physicians recommends avoiding opioids due to the risk of dependency, rebound headaches, and eventual loss of efficacy 11
• The American Academy of Family Physicians also advises against the use of barbiturates due to the risk of dependency and medication overuse headache 11

Treatment Assessment and Duration

• The American Academy of Neurology suggests assessing the efficacy of oral preventive medications after 2-3 months at therapeutic dose, with a strength of evidence level not specified in the article 11

Preventive Pharmacotherapy

• The American Heart Association recommends the use of beta blockers, such as propranolol, metoprolol, atenolol, or bisoprolol, as first-line preventive medications for patients with vestibular migraine, particularly those with comorbid hypertension 11
• The American Academy of Neurology suggests the use of topiramate, 50-100 mg oral daily, as a first-line preventive medication, especially beneficial in obese patients 11
• The American College of Cardiology recommends the use of candesartan, an angiotensin receptor blocker, as a first-line option, particularly useful in hypertensive patients 11
• The International Headache Society recommends the use of flunarizine, 5-10 mg oral once daily, as a second-line preventive medication, based on two randomized clinical trials, and should be considered the preferred preventive option when first-line agents fail 11

Vestibular Migraine Treatment Guidelines

Introduction to Vestibular Migraine Management

• The American Academy of Neurology recommends that patients with vestibular migraine should be educated on the biological basis of the disorder, requiring multimodal therapy 12

Lifestyle and Dietary Modifications

• Regular exercise has been shown to be as effective as pharmacological approaches when combined with other interventions for patients with vestibular migraine, according to the Mayo Clinic Proceedings 12

Patient Education and Management

• The American Academy of Neurology suggests that treatment adherence improves with simplified dosing schedules, and patients should be educated on the importance of adherence for effective management of vestibular migraine 12

Vestibular Migraine Treatment Guidelines

Medication Management

• The American Academy of Neurology recommends onabotulinumtoxinA, with a dose of 155-195 units to 31-39 sites every 12 weeks, for chronic migraine with vestibular symptoms, as the only FDA-approved therapy for prophylaxis of headache in adults with chronic migraine 13
• The Mayo Clinic suggests that common adverse effects of topiramate include cognitive inefficiency, paresthesia, fatigue, and weight loss, with a recommended dose of 50-100 mg oral daily 13
• Limit simple analgesics to fewer than 15 days/month and triptans to fewer than 10 days/month to prevent medication overuse headache, as recommended by the Mayo Clinic 13

Treatment Assessment and Monitoring

• Assess efficacy of oral preventive medications after 2-3 months at therapeutic dose, and encourage patients to maintain a headache diary to facilitate monitoring of migraine attacks and vestibular episodes, as suggested by the Mayo Clinic 13
• Use validated disability tools such as the Migraine Disability Assessment Score and HIT-6 to track treatment response, as recommended by the Mayo Clinic 13

Comorbidity Management

• Identify and manage modifiable risk factors including obesity, medication overuse, caffeine use, obstructive sleep apnea, psychiatric comorbidities (anxiety, depression), and stress, as recommended by the Mayo Clinic 13

Vestibular Migraine Diagnosis and Treatment

Diagnostic Considerations

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that Ménière's disease can be distinguished from vestibular migraine by documented low-to-mid-frequency sensorineural hearing loss on audiometry and longer duration of vertigo attacks (20 minutes to 12 hours) 14
• 35% of Ménière's disease patients also meet criteria for vestibular migraine, and noninvasive therapeutic trials should be considered prior to surgical or inner ear ablative interventions 14

Non-Pharmacological Interventions

• Vestibular rehabilitation may be useful for chronic imbalance between attacks, according to the American Academy of Otolaryngology-Head and Neck Surgery 14

Vestibular Migraine Diagnosis and Characteristics

Migrainous Features and Auditory Symptoms

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that patients with vestibular migraine commonly report photophobia, phonophobia, and visual auras, which helps differentiate it from Ménière's disease 15
• Bilateral auditory symptoms are more common than unilateral in vestibular migraine, and patients may experience perception of difficulty processing sound rather than true hearing loss 15
• Mild or absent hearing loss that remains stable over time is characteristic of vestibular migraine, unlike the fluctuating hearing loss seen in Ménière's disease 15
• Tinnitus may occur in vestibular migraine but is typically less prominent than in Ménière's disease 15

Vestibular Migraine Pharmacotherapy

Preventive Medications

• The American Academy of Neurology recommends topiramate 50-100 mg oral daily for preventive treatment of vestibular migraine, with common adverse effects including cognitive inefficiency, paresthesia, and fatigue 16
• Second-line preventive medications, such as flunarizine 5-10 mg oral once daily, can be used when first-line agents fail or are contraindicated, as suggested by the Nature Reviews Neurology 16

Non-Pharmacological Adjunctive Therapies

• The American Headache Society suggests that non-pharmacological adjunctive therapies, including biobehavioral therapy and neuromodulatory devices, can be used alongside medications or as stand-alone treatment when medications are contraindicated, with some evidence supporting the use of acupuncture, although not superior to sham acupuncture 16

Vestibular Migraine Diagnosis and Management

Diagnostic Criteria

• Central causes of vestibular symptoms, such as stroke or multiple sclerosis, can be identified by red flags including downbeating nystagmus on Dix-Hallpike, direction-changing nystagmus without head position changes, gaze-holding nystagmus, or baseline nystagmus without provocative maneuvers, and additional neurologic findings like dysarthria, dysmetria, dysphagia, sensory/motor loss, or Horner's syndrome, according to the American Academy of Otolaryngology-Head and Neck Surgery 17

Critical Differential Diagnosis

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that central causes of vestibular symptoms can be distinguished from vestibular migraine by the presence of red flags, including downbeating nystagmus on Dix-Hallpike, and additional neurologic findings like dysarthria, dysmetria, dysphagia, sensory/motor loss, or Horner's syndrome 17

Avoidance of Positive Pressure Therapy in Vestibular Migraine

Contraindicated Therapies